Yeji
NDA/BLA filedconf 0.75

reproxalap — NDA/BLA filed

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease
Event date
Date TBD
Sponsor runway
38 mo
$65.0M liquid

Evidence

“standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy clinical trials of reproxalap submitted to the New Drug Application for the treatment of dry eye disease”
Source: 8-K filed 2026-05-01View on EDGAR ↗0001193125-26-199157

Comparable historical nda/bla fileds· last 5 years · same indication

TickerDrugDateOutcome
$ALDXreproxalap2025-07-17unknown
$ALDXreproxalap2024-11-01unknown
$ALDXreproxalap2023-02-07unknown
$ALDXreproxalap2023-02-01unknown

Recent insider activity· ±90 days

No insider Form 4 activity reported on $ALDX in the 90 days around this event.
← All catalysts for $ALDX